| ASAHI KASEI PHARMA CORPORATION Patent applications |
| Patent application number | Title | Published |
|---|
| 20120040387 | METHOD AND REAGENT FOR MEASURING MEVALONIC ACID, 3-HYDROXYMETHYLGLUTARYL COENZYME A, AND COENZYME A - The present invention provides a method for measuring the concentration of an analyte in a test solution wherein the analyte is mevalonic acid and/or 3-hydroxymethylglutaryl coenzyme A, comprising the following steps (p) and (q): (p) a step of allowing an enzyme that catalyzes a reaction represented by Reaction Formula 1 and an enzyme that catalyzes a reaction represented by Reaction Formula 2 to act on a test solution containing mevalonic acid and/or 3-hydroxymethylglutaryl coenzyme A in the presence of a hydrogen acceptor X, a hydrogen donor Y, and coenzyme A; and (q) a step of measuring an amount of: a reduced hydrogen acceptor X that is produced; or an oxidized hydrogen donor Y that is produced; or a hydrogen acceptor X that is decreased; or a hydrogen donor Y that is decreased, wherein the hydrogen donor Y and the reduced hydrogen acceptor X are not the same. | 02-16-2012 |
| 20120015925 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS - A pharmaceutical useful as a therapeutic agent and a preventive agent for hyperlipemia, and a pharmaceutical useful as a therapeutic agent and a preventive agent for hepatic disorders associated with cholestasis, particularly, primary biliary cirrhosis and primary sclerosing cholangitis, and a pharmaceutical useful as a therapeutic agent and a preventive agent for obesity, fatty liver and steatohepatitis are provided. A benzothiazepine or benzothiepine compound represented by the following formula (1A) having a thioamide bond and a quaternary ammonium substituent: | 01-19-2012 |
| 20110184017 | STABLE AQUEOUS SOLUTION COMPOSITION CONTAINING SULFONAMIDE COMPOUND - An aqueous solution composition containing (S)-1-(4-chloro-5-isoquinolinesulfonyl)-3-aminopyrrolidine or (S)-1-(4-chloro-5-isoquinolinesulfonyl)-3-(methylamino)pyrrolidine as an active ingredient, and not containing citric acid or a salt thereof, which has high stability so as to be storable at room temperature. | 07-28-2011 |
| 20110172154 | PREVENTIVE AND/OR THERAPEUTIC AND/OR AGGRAVATION SUPPRESSING AGENT FOR HUMAN ARTHRITIS DEFORMANS - [Object] To provide a medicine that is extremely useful for preventing and/or treating and/or limiting exacerbation of human knee osteoarthritis. | 07-14-2011 |
| 20110171139 | FASUDIL IN COMBINATION THERAPIES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION - Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing pulmonary arterial hypertension and/or stable angina. More particularly, aspects of the present invention are related to therapeutic combinations comprising a Rho-kinase inhibitor, such as fasudil, and one or more additional compounds selected from the group consisting of prostacyclins, such as iloprost, endothelin receptor antagonists, PDE inhibitors, calcium channel blockers, 5-HT | 07-14-2011 |
| 20110159564 | METHOD FOR STABILIZING COENZYME AND COMPOSITION THEREOF - Disclosed is a sugar and/or a sugar alcohol as a substance for suppressing dephosphorylation reaction of a phosphorylated coenzyme. Also disclosed is a method for stabilizing a phosphorylated coenzyme which is characterized by having at least a substance for suppressing dephosphorylation reaction of the phosphorylated coenzyme coexist with the phosphorylated coenzyme. | 06-30-2011 |
| 20100261701 | 8-Substituted isoquinoline derivative and the use thereof - The present invention relates to a compound represented by the following formula (1): | 10-14-2010 |
| 20100222404 | INDAZOLE DERIVATIVE DIHYDROCHLORIDE - There are provided (R)—N-[3-[2-[2-(3-methylindazol-6-yloxy)ethylamino]-1-hydroxyethyl]phenyl]methanesulfonamide dihydrochloride and a crystal thereof, and a crystal of the dihydrochloride salt having one or more major peaks at 2θ selected from the group consisting of approximately 12.8°, 21.8° and 25.0° in the powder X-ray diffraction spectrum. | 09-02-2010 |
| 20100174118 | PROCESS FOR PRODUCTION OF CAROTENOID - A method for producing a composition containing carotenoid at a content of 80% or greater, characterized in performing extraction on a culture of a microorganism, a concentrate of the culture, or a dried substance thereof with at least one selected from the group consisting of lower alcohols, water-containing lower alcohols, lower dialkylketones and ethers; and then washing a precipitate, obtained by concentrating the extract solution, with at least one selected from the group consisting of lower alcohols, water-containing lower alcohols, hydrocarbon-based solvents and lower dialkylketones; and food, a pharmaceutical composition or a cosmetic substance comprising the carotenoid-containing composition. | 07-08-2010 |
| 20100160256 | INDAZOLE COMPOUNDS - Provided are compounds represented by the following formula (A-1) and formula (1), or salts thereof. The compounds of formula (A-1) and formula (1) or salts thereof have 133 adrenergic receptor agonist activity, and thus are useful as therapeutic and prophylactic agent for diabetes mellitus, obesity, hyperlipidemia, depression, diseases caused by gallstones or hypermotility of the biliary tract, diseases caused by hyperactivity of the digestive tract, interstitial cystitis, overactive bladder or urinary incontinence, or as therapeutic and prophylactic agents for diseases concomitant with decreased tears. | 06-24-2010 |
| 20100152265 | INDAZOLE DERIVATIVES - Compounds represented by the Formula (A-1) and the Formula (1) or salt thereof are provided. The compounds represented by the Formula (A-1) and the Formula (1) or salt thereof have a β3 adrenergic receptor agonist activity, and therefore are useful as an agent for the prevention and treatment of diabetes, obesity, hyperlipidemia, depression, biliary stone, a disorder derived from hyperactivity of biliary tract, a disorder derived from hyperactivity of digestive tract, interstitial cystitis, overactive bladder, urinary incontinence or a disorder derived from decreased tear secretion, etc. | 06-17-2010 |
| 20100152106 | AGENT FOR THERAPY AND/OR IMPROVEMENT OF DISSEMINATED INTRAVASCULAR COAGULATION - It is an object of the present invention to provide a therapeutically effective agent for therapy and/or improvement of DIC, or a method for treating and/or improving DIC. The present invention provides an agent for therapy and/or improvement of disseminated intravascular coagulation comprising thrombomodulin as an active ingredient, which is administered to antithrombin-reduced patients having a low plasma antithrombin activity of less than 50%. | 06-17-2010 |
| 20100145020 | METHOD FOR PRODUCING HIGH-PURITY SOLUBLE THROMBOMODULIN - It is an object of the present invention to obtain a soluble thrombomodulin substantially not containing a denatured product of soluble thrombomodulin that may be generated under acidic conditions. The present invention provides a method for producing soluble thrombomodulin substantially not containing a denatured product of the soluble thrombomodulin that may be generated under acidic conditions, from a soluble thrombomodulin-containing material that contains or is suspected to contain the denatured product of the soluble thrombomodulin, which comprises; a step of subjecting the soluble thrombomodulin-containing material to an anion exchanger or hydroxyapatite; and a step of carrying out linear gradient elution, stepwise gradient elution, or gradient elution in which linear gradient elution is combined with stepwise gradient elution under separation conditions in which the denatured product of the soluble thrombomodulin can be separated, wherein said gradient is a gradient of salt concentration, so as to obtain an elution fraction containing soluble thrombomodulin that does not substantially contain the denatured product of the soluble thrombomodulin, either (a) after the position of a fraction has previously been confirmed, or (b) while confirming the elution fraction. | 06-10-2010 |
| 20100093819 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF - A compound represented by the following general formula (1) or a salt thereof, which has superior inhibitory activity against type 4 PLA | 04-15-2010 |
| 20100093789 | SULFONAMIDE COMPOUND - A compound represented by the formula (1) [A represents a nitrogen-containing saturated ring; m represents an integer of 0 to 2; n represents an integer of 1 to 4; G | 04-15-2010 |
| 20100061969 | DIETARY SUPPLEMENT, ANTI-FATIGUE AGENT OR PHYSICAL ENDURANCE ENHANCER, FUNCTIONAL FOOD, OR COSMETIC - Provided is an anti-fatigue agent or a physical endurance enhancer or a functional food having an anti-fatigue effect or a physical endurance-enhancing effect. Specifically provided are: a composition comprising phosphatidylinositol and coenzyme Q10; an anti-fatigue agent or a physical endurance enhancer comprising phosphatidylinositol and coenzyme Q10 as active ingredients; a functional food having an anti-fatigue effect or a physical endurance-enhancing effect, which comprises the compounds as active ingredients; use of phosphatidylinositol and coenzyme Q10 for the preparation of a composition having an anti-fatigue effect or a physical endurance-enhancing effect; and a method of enhancing an anti-fatigue effect or physical endurance, which includes ingesting a composition comprising those compounds as active ingredients. | 03-11-2010 |
| 20100048893 | Substituted arylalkanoic acid derivatives and use thereof - A compound represented by the formula (I): | 02-25-2010 |
| 20100041725 | STABLE PHARMACEUTICAL COMPOSITION - A pharmaceutical composition comprising a compound represented by the general formula (I): | 02-18-2010 |
| 20100029733 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS - A nitrogen-containing bicyclic heterocyclic compound represented by the following formula (1) is provided. When the compound or a salt thereof is administered to a human being or an animal, the compound has a strong antagonistic action against EP1 receptors, and is useful, for example, as an active ingredient of a medicine for the prevention and/or treatment of overactive bladder. The compound is also useful as an active ingredient of a medicine for the prevention and/or treatment of symptoms such as frequency urinary, urinary urgency, or urinary incontinence. | 02-04-2010 |
| 20100029690 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS - Nitrogen-containing heterocyclic compounds represented by the following Formula (1) are provided. The compounds or salts thereof have a strong EP1 antagonistic activity when they are administered to a human or an animal, and they are useful as an effective component of a pharmaceutical agent for prophylaxis and/or treatment of an overactive bladder, for example. Furthermore, they are useful as an effective component of a pharmaceutical agent for the prophylaxis and/or treatment of symptoms including frequent urination, urinary urgency and urinary incontinence. | 02-04-2010 |
| 20100022601 | SULFONAMIDE COMPOUNDS AND THE USE - The sulfoneamide compounds having the following Formula (1), which can be used as an effective component of a CaSR antagonizing agent useful for prophylaxis and/or treatment of bone disorders including osteoporosis and etc., are provided. The compounds have an excellent activity of promoting PTH secretion. In addition, the compounds are useful as an effective component of a medicament for the prophylaxis and/or treatment of bone disorders such as osteoporosis, bone fracture, hypoparathyroidism and the like. | 01-28-2010 |
| 20090317851 | HEMOGLOBIN A1C DETERMINATION METHOD, ENZYME TO BE USED THEREFOR, AND PRODUCTION METHOD THEREOF - There is provided a method for specifically determining a glycated β-chain N-terminal of glycated hemoglobin using enzymes without a separation operation, and a determination reagent kit therefor. A protease that cleaves a glycated amino acid and/or a glycated peptide from a glycated β-chain N-terminal without substantially cleaving a glycated amino acid or a glycated peptide from a glycated α-chain N-terminal of glycated hemoglobin or a fragment thereof is screened. The method of specifically determining a glycated β-chain N-terminal of glycated hemoglobin and the determination reagent kit are provided by using the protease obtained by the screening method. According to the present invention, a glycated β-chain N-terminal of glycated hemoglobin can specifically be determined without a separation operation. | 12-24-2009 |
| 20090298894 | AMINO ACID COMPOUNDS - [Problem] To provide novel compounds that are S1P1 receptor agonists and exhibit an immunosuppressive activities by inducing lymphocyte sequestration in secondary lymphoid tissues. In addition, to provide a pharmaceutical agent which comprises the compounds as an effective component, in particular to provide a therapeutic and/or prophylactic agent for an autoimmune disease and the like. | 12-03-2009 |
| 20090246783 | METHOD OF MEASURING PYROPHOSPHATE - Provided is a novel and useful method of measuring pyrophosphate in a sample. There may be provided a novel and useful method of measuring pyrophosphate in a sample using pyruvate orthophosphate dikinase, nicotinamide-nucleotide adenylyltransferase, and dehydrogenase. | 10-01-2009 |
| 20090192154 | SULTAM DERIVATIVES - A sultam derivative of Formula (1) described below having inhibitory action for aggrecanase activity is provided. The sultam derivative of Formula (1) and a salt thereof exhibit strong inhibitory action for aggrecanase activity in a living body of a mammalian animal including human, and is useful, for example, as an active ingredient of a pharmaceutical agent for preventing and/or treating various diseases caused by degradation of aggrecan. | 07-30-2009 |
| 20090156823 | Sulfonamide compound and crystal thereof - (S)-1-(4-Chloro-5-isoquinolinesulfonyl)-3-(methylamino)pyrrolidine monohydrochloride and a crystal thereof, and a crystal of the aforementioned monohydrochloride having a major peak or peaks at one or more positions selected from the group consisting of positions where 2θs are about 13.9°, 21.5°, 21.7°, 22.4°, 22.8°, 24.5° and 35.0° in a powder X-ray diffraction spectrum, which have excellent properties as active ingredient of a medicament for prophylactic and/or therapeutic treatment of glaucoma and the like. | 06-18-2009 |
| 20090062530 | Substituted arylalkanoic acid derivatives and use thereof - A compound represented by the formula (I): | 03-05-2009 |
| 20090054401 | Substituted bicyclic derivatives and use thereof - [Object] To provide a compound having prostaglandin production-suppressing action and leukotriene production-suppressing action.
| 02-26-2009 |
| 20090048223 | Sulfonamide compound - A compound represented by the formula (1) [A represents a nitrogen-containing saturated ring; m represents an integer of 0 to 2; n represents an integer of 1 to 4; G | 02-19-2009 |
| 20090042279 | METHOD OF DETECTING MILD IMPAIRED GLUCOSE TOLERANCE OR INSULIN SECRETORY DEFECT - It is intended to provide a noninvasive method of conveniently detecting mild impaired glucose tolerance and/or insulin hyposecretion at the early stage with the use of an enzyme. Namely, mild impaired glucose tolerance and/or insulin hyposecretion at the early stage are detected by quantifying myoinositol secreted into the urine before loading glucose and after loading glucose for a definite period of time with the use of a reagent and comparing the increase (or the increase ratio) in the myoinositol content thus measured with a characteristic level which has been preliminarily determined in normal subjects. | 02-12-2009 |
| 20080319083 | MEDICINE FOR TRANSNASAL ADMINISTRATION - The object is to provide an SNRI-containing preparation which has a higher absorbability compared to a conventional SNRI preparation, produces its effect rapidly, and is readily administered to a patient who is hard to be administered via an oral route. | 12-25-2008 |
| 20080318256 | Method for Stabilizing Coenzyme and Composition Therefor - Disclosed is a sugar and/or a sugar alcohol as a substance for suppressing dephosphorylation reaction of a phosphorylated coenzyme. Also disclosed is a method for stabilizing a phosphorylated coenzyme which is characterized by having at least a substance for suppressing dephosphorylation reaction of the phosphorylated coenzyme coexist with the phosphorylated coenzyme. | 12-25-2008 |
| 20080295259 | METHOD FOR STABILIZING LEUCO-TYPE COLORANT - Provided are a method of stabilizing a leuco dye storable as a liquid for a long time, a method of reducing nonspecific color development thereof at a time of a color development reaction, and a stable liquid reagent composition using the methods. The inventors of the present invention found that coexistence of the leuco dye with a specific reducing agent resulted in suppression of self color development and its remarkably improved stability in a solution, and that when a color development reaction of the leuco dye with hydrogen peroxide was performed, coexistence of the leuco dye, in a reaction solution, with another dye which had an absorption spectrum not influencing a measurement wavelength of the leuco dye and did not react with hydrogen peroxide suppressed nonspecific color development and lowered a reagent blank value, which was applied to an analytical reagent. | 12-04-2008 |
| 20080242660 | Therapeutic Agent for Vasospasm Accompanying Bypass Operation - An agent and composition for the prevention of and/or treatment for vasospasm accompanying a bypass operation, which contains as an active ingredient either a compound represented by the following general formula (I) or an acid addition salt or hydrate thereof. R | 10-02-2008 |
| 20080234483 | Fasudil-Containing Preparation and Method of Improving Stability Thereof - Fasudil-containing preparations that despite the us of a container excelling in the visibility of contents without particularly blocking of light, exhibit high stability against light; and a method of improving the stability of the preparations against light of storing the same. By regulating the pH value of aqueous solution of fasudil charged in a colorless transparent container to ≦5.5, there can be provided fasudil-containing preparations excelling in stability against light; and can be provided a method of improving the stability of the aqueous solution of fasudil against light, or storing the same. | 09-25-2008 |
| 20080200535 | Amine Compounds - There is provided a compound exhibiting an activity of suppressing immune response with reduced adverse drug reactions, which compound is useful in the chemotherapy for preventing or treating, for example, a wide range of various autoimmune diseases including systemic erythematodes, chronic rheumatoid arthritis, Type I diabetes, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis or other disorders, or chronic inflammatory diseases, or cancers, lymphoma or leukemia, or resistance to organ or tissue transplantation or rejection against transplantation. | 08-21-2008 |
